Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34376375&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs Second Pandemic Wave in Spain #MMPMID34376375
Clin Lymphoma Myeloma Leuk 2021[Oct]; 21 (10): e801-e809 PMID34376375show ga
BACKGROUND AND OBJECTIVE: SARS-CoV-2 infection has bimodal distribution in Europe with a first wave in March to June 2020 and a second in September 2020 to February 2021. We compared the frequency, clinical characteristics and outcomes of adults with acute lymphoblastic leukemia (ALL) and infection in the first vs. second pandemic waves in Spain. PATIENTS AND METHODS: In this prospective study the characteristics of ALL and COVID-19 infection, comorbidities, treatment and outcome in the two periods were compared. The study ended when vaccination against SARS-CoV-2 was implemented in Spain. RESULTS: Twenty eight patients were collected in the first wave and 24 in the second. The median age was 46.5 years (range 20-83). Patients from the first wave had a trend to more severe ALL (higher frequency of patients under induction or submitted to transplantation or under immunosuppressive therapy). No significant differences were observed in need for oxygen support, intensive care unit (ICU) requirement, days in ICU and time to COVID-19 infection recovery. Seventeen patients (33%) died, with death attributed to COVID infection in 15 (29%), without significant differences in the 100 day overall survival (OS) probabilities in the two waves (68% +/- 17% vs. 56% +/- 30%). The only prognostic factor for OS identified by was the presence of comorbidities at COVID-19 infection (HR: 5.358 [95% CI: 1.875- 15.313]). CONCLUSION: The frequency and mortality of COVID-19 infection were high in adults with ALL, without changes over time, providing evidence in favor of vaccination priority for these patients.
|Adult[MESH]
|Aged[MESH]
|Aged, 80 and over[MESH]
|COVID-19/*epidemiology/therapy/virology[MESH]
|Comorbidity[MESH]
|Female[MESH]
|Humans[MESH]
|Intensive Care Units/*statistics & numerical data[MESH]
|Kaplan-Meier Estimate[MESH]
|Male[MESH]
|Middle Aged[MESH]
|Multivariate Analysis[MESH]
|Outcome Assessment, Health Care/methods/*statistics & numerical data[MESH]
free
free
free
Clin+Lymphoma+Myeloma+Leuk 2021 ; 21 (10): e801-e809
